肝脏脂肪定量:我们处于什么位置
本文综述非酒精性脂肪性肝病的临床负担及无创影像学定量肝脏脂肪的作用。经皮肝活检是当前参考标准,但属有创检查且采样变异大。化学位移编码MRI衍生的质子密度脂肪分数(MRI-PDFF)作为定量影像生物标志物日益被接受,CT对偶然发现的脂肪变性有重要作用,定量超声的实际优势前景广阔。
要点
- MRI-PDFF是化学位移编码MRI衍生的质子密度脂肪分数,作为肝脏脂肪定量影像生物标志物日益被接受。
- 经皮肝活检是NAFLD评估的当前参考标准,但为有创操作且采样变异大。
- CT是检测偶然性脂肪变性的重要影像方法,定量超声的实际优势前景广阔。
核心结论
- MRI-PDFF作为肝脏脂肪的定量影像生物标志物日益被接受,正在改变日常临床实践并影响NAFLD新疗法的开发。
- 理解NAFLD的疾病负担和影像学的作用可能启动重要干预,以避免NAFLD的肝脏和肝外并发症。
研究设计与样本
- 综述类文章,回顾NAFLD的临床负担及用于定量肝脏脂肪的无创影像技术。
- 经皮肝活检是NAFLD评估的当前参考标准。
诊断标准与关键数值
- 肝细胞内甘油三酯过度蓄积即肝脏脂肪变性,影响全球约十亿人。
- 在无继发病因时使用非酒精性脂肪性肝病(NAFLD)这一术语。
- 在定量肝脏脂肪的方法中,基于化学位移编码MRI(CSE-MRI)的质子密度脂肪分数(PDFF)显示出最大前景。
临床应用与阅片要点
- MRI-PDFF作为定量影像生物标志物日益被接受,正在改变日常临床实践。
- CT是检测偶然性脂肪变性的重要影像方法。
- 理解NAFLD疾病负担和影像学作用可能启动重要干预,以避免肝脏和肝外并发症。
局限性
- 经皮肝活检为有创操作,伴有并发症,且存在高采样变异性,对临床常规和药物疗效研究不实用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Excessive intracellular accumulation of triglycerides in the liver, or hepatic steatosis, is a highly prevalent condition affecting approximately one billion people worldwide. In the absence of secondary cause, the term nonalcoholic fatty liver disease (NAFLD) is used. Hepatic steatosis may progress into nonalcoholic steatohepatitis, the more aggressive form of NAFLD, associated with hepatic complications such as fibrosis, liver failure and hepatocellular carcinoma. Hepatic steatosis is associated with metabolic syndrome, cardiovascular disease and represents an independent risk factor for type 2 diabetes, cardiovascular disease and malignancy. Percutaneous liver biopsy is the current reference standard for NAFLD assessment; however, it is an invasive procedure associated with complications and suffers from high sampling variability, impractical for clinical routine and drug efficiency studies. Therefore, noninvasive imaging methods are increasingly used for the diagnosis and monitoring of NAFLD. Among the methods quantifying liver fat, chemical-shift-encoded MRI (CSE-MRI)-based proton density fat-fraction (PDFF) has shown the most promise. MRI-PDFF is increasingly accepted as quantitative imaging biomarker of liver fat that is transforming daily clinical practice and influencing the development of new treatments for NAFLD. Furthermore, CT is an important imaging method for detection of incidental steatosis, and the practical advantages of quantitative ultrasound hold great promise for the future. Understanding the disease burden of NAFLD and the role of imaging may initiate important interventions aimed at avoiding the hepatic and extrahepatic complications of NAFLD. This article reviews clinical burden of NAFLD, and the role of noninvasive imaging techniques for quantification of liver fat.
引用
- Starekova J, Reeder SB. Liver fat quantification: where do we stand? Abdom Radiol (NY). 2020. PMID: 33025153. doi:10.1007/s00261-020-02783-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。